GRAIL (NASDAQ:GRAL) CEO Robert Ragusa Sells 37,504 Shares of Stock

GRAIL, Inc. (NASDAQ:GRAL) CEO Robert Ragusa sold 37,504 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $50.17, for a total value of $1,881,575.68. Following the completion of the sale, the chief executive officer owned 650,525 shares of the company’s stock, valued at approximately $32,636,839.25. This represents a 5.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

GRAIL Stock Up 0.2%

GRAL stock opened at $52.76 on Wednesday. GRAIL, Inc. has a twelve month low of $20.44 and a twelve month high of $118.84. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -4.72 and a beta of 5.18. The firm’s fifty day simple moving average is $91.27 and its two-hundred day simple moving average is $77.46.

GRAIL (NASDAQ:GRAL) last released its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. The firm had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. As a group, equities research analysts expect that GRAIL, Inc. will post -15.15 EPS for the current year.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: GRAIL granted inducement restricted stock units covering 19,500 shares to 20 recently hired non‑executive employees under NASDAQ Rule 5635(c)(4). The award is small relative to market cap and appears intended to attract talent rather than materially dilute shareholders. GRAIL Announces Inducement Grants
• Neutral Sentiment: Reported short‑interest data contains obvious errors (shows 0 shares short and NaN changes), so it provides no reliable signal; treat the published short‑interest figures as suspect until corrected by the data provider or exchange.
• Negative Sentiment: Three senior executives sold shares on March 2: CEO Robert P. Ragusa sold 37,504 shares at an average price of $50.17 (~$1.88M), CFO Aaron Freidin sold 9,573 shares at $50.17 (~$480k), and President Joshua J. Ofman sold 17,002 shares at $50.16 (~$853k). Each sale reduced their holdings by a few percentage points. Insider selling can pressure sentiment (perception of executives taking gains or diversifying), though filings indicate these were disclosed transactions rather than unreported trades. SEC filings: Ragusa Form 4 Freidin Form 4 Ofman Form 4
• Negative Sentiment: Law firm Levi & Korsinsky announced an investigation into GRAIL over possible securities‑law violations tied to prior guidance statements (specifically CFO comments on cash‑burn guidance for 2025). Such probes can increase legal risk, create headline volatility, and prompt investor caution until details or outcomes are clarified. Levi & Korsinsky Investigation

Analysts Set New Price Targets

A number of brokerages recently issued reports on GRAL. Morgan Stanley decreased their price target on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Canaccord Genuity Group decreased their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, February 20th. TD Cowen started coverage on shares of GRAIL in a research note on Thursday, February 19th. They set a “hold” rating and a $114.00 target price for the company. Finally, Guggenheim upped their price target on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $90.17.

Institutional Investors Weigh In On GRAIL

Institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of GRAIL by 17.7% during the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after buying an additional 13,264 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in GRAIL by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after acquiring an additional 623 shares during the period. NewEdge Advisors LLC lifted its stake in GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after acquiring an additional 1,401 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in GRAIL by 37.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock worth $2,362,000 after acquiring an additional 25,177 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in GRAIL by 5.5% during the 2nd quarter. Teacher Retirement System of Texas now owns 8,538 shares of the company’s stock worth $439,000 after acquiring an additional 447 shares in the last quarter.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.